Drogheda

Crohns disease is a chronic condition causing severe inflammation in the digestive tract, mainly affecting the bowels, and leading to symptoms like belly pain, diarrhea, tiredness, and weight loss. This trial is evaluating several targeted therapies for adults with moderate to severe Crohns disease. The study involves around 540 adults and aims to assess how well these treatments work and monitor any side effects over time. The treatments being studied include risankizumab, trosunilimab, lutikizumab, and ABBV-8736. These medicines are given either by injection under the skin or infusion into a vein, depending on the drug. Participants will be randomly assigned to receive one of several treatment combinations or monotherapies, with some continuing risankizumab alone for up to 72 weeks. Participants will attend regular hospital or clinic visits for medical assessments, blood tests, and endoscopies to check the effects of treatment. Researchers will also monitor side effects, collect daily diary information, and use questionnaires. Key outcomes include the percentage of participants achieving endoscopic remission by week 12 and tracking adverse events for up to about 96 weeks.

Researchers are studying VE303, a live biotherapeutic product made of nonpathogenic bacteria strains, to evaluate its safety and effectiveness in preventing recurrent Clostridioides difficile infection CDI. This Phase 3 trial compares VE303 to a placebo in participants who recently completed standard antibiotic treatment for CDI. The study focuses on two groups those with recurrent CDI and individuals at high risk for primary CDI recurrence. Participants will receive either VE303 or a matching placebo capsule three times daily for 14 days, following 10 to 21 days of standard antibiotic therapy for CDI. VE303 capsules contain the study bacteria, while placebo capsules contain a non-active substance identical in appearance. Both groups complete this treatment regimen as part of the trial. During the study, participants are monitored for safety and CDI recurrence up to 8 weeks after treatment starts. Researchers collect stool samples and track symptoms to assess recurrence rates. The study uses a randomized, double-blind design to ensure unbiased results, and participants are followed closely through the treatment and observation periods, which last several weeks.

The trial investigates the safety and effects of MTX-463, an antibody targeting WISP1, in adults aged 40 or older with idiopathic pulmonary fibrosis IPF. This Phase 2a study compares MTX-463 to a placebo, allowing participants to continue approved IPF treatments like pirfenidone, nintedanib, or nerandomilast if stable. Participants must meet specific diagnostic criteria and lung function thresholds to join. Participants receive either MTX-463 or placebo through intravenous infusions every 4 weeks from Day 0 to Week 20. The treatment phase concludes with a visit at Week 24, followed by a safety follow-up at Week 28. Lung function tests including forced vital capacity FVC and lung fibrosis assessments are done at screening, baseline, and during treatment visits. Blood samples are collected regularly to monitor safety and drug levels. Throughout the study, participants attend visits every 4 weeks for assessments of lung function, safety labs, and WISP1 protein levels. The main outcome measures include changes in FVC after 24 weeks and safety profiles over 28 weeks. Participant involvement spans from screening through final safety follow-up, with careful monitoring to evaluate the study drugs impact and tolerability in IPF.